These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Persistent ascites resolving with gonadotropin-releasing-hormone-agonist 18 months after hospitalization for severe ovarian hyperstimulation syndrome. Comba C; Ugurlucan FG; Bastu E; Iyibozkurt AC; Topuz S Arch Gynecol Obstet; 2014 Jan; 289(1):223-5. PubMed ID: 23846619 [TBL] [Abstract][Full Text] [Related]
5. GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study. Giles J; Requena A; García-Velasco JA; Pacheco A; Pellicer J; Pellicer A Fertil Steril; 2009 Apr; 91(4 Suppl):1366-9. PubMed ID: 18692821 [TBL] [Abstract][Full Text] [Related]
6. Ovarian hyperstimulation: effects of GnRH analogues. Does triggering ovulation with gonadotrophin-releasing hormone analogue prevent severe ovarian hyperstimulation syndrome? Casper RF Hum Reprod; 1996 Jun; 11(6):1144-6. PubMed ID: 8671408 [No Abstract] [Full Text] [Related]
7. Ovarian hyperstimulation: effects of GnRH analogues. Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications. Kol S; Lewit N; Itskovitz-Eldor J Hum Reprod; 1996 Jun; 11(6):1143-4. PubMed ID: 8671407 [No Abstract] [Full Text] [Related]
8. Ovarian hyperstimulation: effects of GnRH analogues. Triggering the final stage of ovulation using gonadotrophin-releasing hormone analogues: effective dose, prevention of ovarian hyperstimulation syndrome and the luteal phase. Ben-Arie A; Weissman A; Shoham Z Hum Reprod; 1996 Jun; 11(6):1146-8. PubMed ID: 8671409 [No Abstract] [Full Text] [Related]
9. Leuprolide acetate elevates prolactin during ovarian stimulation with gonadotropins. Meldrum DR; Cedars MI; Hamilton F; Huynh D; Wisot A; Marr B J Assist Reprod Genet; 1992 Jun; 9(3):251-3. PubMed ID: 1525456 [TBL] [Abstract][Full Text] [Related]
10. Long-term management of adenomyosis with a gonadotropin-releasing hormone agonist: a case report. Nelson JR; Corson SL Fertil Steril; 1993 Feb; 59(2):441-3. PubMed ID: 8425643 [TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation: low-dose side effects in women and monkeys. Navot D; Rosenwaks Z; Anderson F; Hodgen GD Fertil Steril; 1991 Jun; 55(6):1069-75. PubMed ID: 1828042 [TBL] [Abstract][Full Text] [Related]
12. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639 [TBL] [Abstract][Full Text] [Related]
13. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Itskovitz-Eldor J; Kol S; Mannaerts B Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996 [TBL] [Abstract][Full Text] [Related]
14. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175 [TBL] [Abstract][Full Text] [Related]
15. Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome. Kasum M; Orešković S; Franulić D; Čehić E; Lila A; Vujić G; Grgić F Acta Clin Croat; 2017 Mar; 56(1):133-142. PubMed ID: 29120551 [TBL] [Abstract][Full Text] [Related]
16. [Protocol with GnRH-antagonist and ovulation trigger with GnRH-agonist in risk patients--a reliable method of prophylactic of OHSS]. Kovachev E Akush Ginekol (Sofiia); 2008; 47(4):16-9. PubMed ID: 19227761 [TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone agonist plus add-back sex steroids to reduce risk of breast cancer. Spicer D; Shoupe D; Pike M J Natl Cancer Inst; 1991 Dec; 83(23):1763. PubMed ID: 1770556 [No Abstract] [Full Text] [Related]
18. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study. Lewit N; Kol S; Manor D; Itskovitz-Eldor J Hum Reprod; 1996 Jul; 11(7):1399-402. PubMed ID: 8671474 [TBL] [Abstract][Full Text] [Related]
19. Preventing ovarian hyperstimulation with gonadotropin-releasing hormone agonist trigger: is anything perfect? Filicori M Fertil Steril; 2014 Apr; 101(4):936-7. PubMed ID: 24613536 [No Abstract] [Full Text] [Related]
20. [Comparison of 3 long ovarian stimulation protocols for in vitro fertilization using a delayed acting GnRH analogue]. Vauthier-Brouzes D; Lefebvre G Contracept Fertil Sex; 1993 Mar; 21(3):209-12. PubMed ID: 7951614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]